Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in Metastatic/Recurrent Head and Neck Cancer
NCT00114283Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started Mar 2005; status: completed.
02
Drugs
lapatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00114283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114283.